Te-Chun Shen1,2,3, Wen-Shin Chang3, Chia-Wen Tsai3, Che-Yi Chao4, Yi-Ting Lin3, Chieh-Lun Hsiao3, Che-Lun Hsu5, Wei-Chun Chen2, Te-Chun Hsia6,3, DA-Tian Bau7,3,8. 1. Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. 3. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C. 4. Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, R.O.C. 5. Department of Otolaryngology, China Medical University Hospital, Taichung, Taiwan, R.O.C. 6. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. datian@mail.cmuh.org.tw artbau2@gmail.com. 7. Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. datian@mail.cmuh.org.tw artbau2@gmail.com. 8. Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
Abstract
BACKGROUND/AIM: Up-regulation of metallo-proteinase (MMP) proteins has been shown in various types of solid cancers and the genotype of MMP1 has been associated with the risk of solid cancers. The contribution of MMP1 genotype to lung cancer has been investigated in various countries, though, to our knowledge, not in Taiwan. Therefore, in this study, we focused on the contribution of a polymorphism in the promoter region of MMP1 to lung cancer risk in Taiwan population. PATIENTS AND METHODS: Genomic DNA was isolated from peripheral blood of 358 patients with lung cancer and 716 healthy individuals (non-cancer patients). MMP1 rs1799750 polymorphic genotypes of each sample were determined using the typical methodology of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: The percentages of 2G/2G, 1G/2G, and 1G/1G for MMP1 -1607 genotypes were 34.4%, 41.3% and 24.3% in the disease group and 33.9%, 44.0%, and 22.1% in the control group (p trend=0.6298), respectively. The results of carrier comparisons in dominant and recessive models also support the findings that 1G or 2G appears not to be a determinant allelic biomarker for Taiwan lung cancer. CONCLUSION: The MMP1 -1607 1G allele is a non-significant protective biomarker for lung cancer in Taiwan. Copyright
BACKGROUND/AIM: Up-regulation of metallo-proteinase (MMP) proteins has been shown in various types of solid cancers and the genotype of MMP1 has been associated with the risk of solid cancers. The contribution of MMP1 genotype to lung cancer has been investigated in various countries, though, to our knowledge, not in Taiwan. Therefore, in this study, we focused on the contribution of a polymorphism in the promoter region of MMP1 to lung cancer risk in Taiwan population. PATIENTS AND METHODS: Genomic DNA was isolated from peripheral blood of 358 patients with lung cancer and 716 healthy individuals (non-cancerpatients). MMP1rs1799750 polymorphic genotypes of each sample were determined using the typical methodology of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: The percentages of 2G/2G, 1G/2G, and 1G/1G for MMP1 -1607 genotypes were 34.4%, 41.3% and 24.3% in the disease group and 33.9%, 44.0%, and 22.1% in the control group (p trend=0.6298), respectively. The results of carrier comparisons in dominant and recessive models also support the findings that 1G or 2G appears not to be a determinant allelic biomarker for Taiwan lung cancer. CONCLUSION: The MMP1 -1607 1G allele is a non-significant protective biomarker for lung cancer in Taiwan. Copyright